Proteomics International Laboratories Ltd (ASX: PIQ) has announced the publication of a peer-reviewed Australian clinical utility study demonstrating that the PromarkerD blood test provides actionable information that significantly changes how doctors manage patients with type 2 diabetes at risk of diabetes-related chronic kidney disease (CKD).
This article was originally published on MedicalXpress.com

